Study supports allergy vaccine using genetically engineered pollen

08/10/2004 | Forbes

Researchers report the first-ever trial on an allergy vaccine developed from genetically engineered pollen shows promise in treating the condition by triggering a strong immune response in the body. The vaccine is seen as a replacement for immunotherapy, a common treatment for allergies that sometimes can make the problem worse.

View Full Article in:

Forbes

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Regional Director, Southeastern Region - State Affairs
America's Health Insurance Plans (AHIP)
Washington, DC
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Multiple Locations, SL_Multiple Locations
Market Intelligence Manager
Olympus Corporation of the Americas
Southborough, MA